Xin-Feng Wang

Xin-Feng Wang

Auto-generated profile, based on publicly available information

Xin-Feng Wang

Department of Chemistry and Research Center for Chemical Biology and Omics Analysis, College of Science, Southern University of Science and Technology, Shenzhen, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2024 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
XWXin-Feng Wang
Xin-Feng Wang
CHChaopeng Hu
Chaopeng Hu
JLJiancheng Li
Jiancheng Li
RWRui Wei
Rui Wei
XZXin Zhang
Xin Zhang
LLLiu Leo Liu
Liu Leo Liu

25 August 2021 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
CLChengming Liu
Chengming Liu
SWSihui Wang
Sihui Wang
SZSufei Zheng
Sufei Zheng
XWXinfeng Wang
Xinfeng Wang
JHJianbin Huang
Jianbin Huang
JHJie He
Jie He
A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma

1 January 2016 in Clinics
Verified
Journal Article
Open access
RLRuolin Li
Ruolin Li
JWJunli Wang
Junli Wang
XWXinfeng Wang
Xinfeng Wang
MWMao-Shui Wang
Mao-Shui Wang
Delay in the treatment of pleural infection may contribute to its high mortality. In this retrospective study, we aimed to evaluate the diagnostic accuracy of pleural adenosine deaminase in discrimination between Gram-negative and Gram-positive bacterial infections of the pleural space prior to selecting antibiotics. A total of 76 patients were enrolled and grouped into subgroups according to Gram staining: 1) patients with Gram-negative bacterial infections, aged 53.2±18.6 years old, of whom 44.7% had empyemas and 2) patients with Gram-positive bacterial infections, aged 53.5±21.5 years old, of whom 63.1% had empyemas. The pleural effusion was sampled by thoracocentesis and then sent for adenosine deaminase testing, biochemical testing and microbiological culture. The Mann-Whitney U test was used to examine the differences in adenosine deaminase levels between the groups. Correlations between adenosine deaminase and specified variables were also quantified using Spearman's correlation coefficient. Moreover, receiver operator characteristic analysis was performed to evaluate the diagnostic accuracy of pleural effusion adenosine deaminase. Mean pleural adenosine deaminase levels differed significantly between Gram-negative and Gram-positive bacterial infections of the pleural space (191.8±32.1 U/L vs 81.0±16.9 U/L, p<0.01). The area under the receiver operator characteristic curve was 0.689 (95% confidence interval: 0.570, 0.792, p<0.01) at the cutoff value of 86 U/L. Additionally, pleural adenosine deaminase had a sensitivity of 63.2% (46.0-78.2%); a specificity of 73.7% (56.9-86.6%); positive and negative likelihood ratios of 2.18 and 0.50, respectively; and positive and negative predictive values of 70.6% and 66.7%, respectively. Pleural effusion adenosine deaminase is a helpful alternative biomarker for early and quick discrimination of Gram-negative from Gram-positive bacterial infections of the pleural space, which is useful for the selection of antibiotics.

10 September 2014 in Journal of Immunoassay and Immunochemistry
Verified
Journal Article
Closed access
JJJin Jiao
Jin Jiao
MWMao-Shui Wang
Mao-Shui Wang
XYXiao-Guang Yang
Xiao-Guang Yang
XWXin-Feng Wang
Xin-Feng Wang
The study evaluated tuberculosis specific antigen (TB-SA) antibody in lymphocyte supernatant (ALS) assay for diagnosis of pulmonary tuberculosis (PTB). The mean concentration of TB-SA ALS in PTB patients was significantly higher than that of two control groups (non-PTB patients and healthy subjects, P < 0.001). The area under the curve of the ALS assay were 0.960 (0.904–0.988, PTB vs healthy subjects), and were 0.822 (0.739–0.887, PTB vs Non-PTB patients), respectively. Our data indicated the ALS assay for TB-SA can be used as a screening test and is a useful adjunct to current tests for diagnosis of PTB.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
XWXinfeng Wang
Xinfeng Wang
YLYuan Li
Yuan Li
RJRunsen Jin
Runsen Jin
NSNan Sun
Nan Sun
JHJie He
Jie He
Recently, a novel oral, irreversible pan-HER tyrosine kinase inhibitor, pyrotinib, has shown anticancer effects on HER2-mutant non-small cell lung cancer (NSCLC) patients, but the explicit responses of lung cancer cells towards pyrotinib treatment are barely investigated. In our current study, we employed single-cell RNA sequencing to profile the longitudinal transcriptomic dynamics of lung cancer cells during the pyrotinib treatment, unraveling the potential resistance mechanisms. We treated a lung adenocarcinoma cell line, H358, with pyrotinib at doses of 100nM, 200nM, 500nM, and 1000nM every four days, respectively. Then, the untreated cells (P0) as well as longitudinal samples after each administration (P4, P8, P12, P16) were harvested for further analysis. After quality control, a total of 41,804 cells were sequenced and included for further analysis. The differentially expressed genes were determined using MAST and the differentially enriched cancer hallmark signatures based on single-sample Gene Set Variation Analysis (ssGSVA) were identified. The single-cell data revealed that the untreated cells (Sample P0) and persistent cells (Sample P16) had stable and distinct gene expression patterns, while cells during the course of treatment shared similar expression features at a transitional state. Several cancer driver genes were found to be aberrantly regulated during the administration, like EPHA2, CDKN2A, CDK4, PTEN, and MYC. Also, some pathways related to immune response were suppressed after pyrotinib treatment, including interferon alpha response, interferon gamma response, TNFA signaling via NF-κB, and inflammatory response. Intriguingly, CD274 (the gene encoding PD-L1) and LGALS9 were found to significantly decrease after pyrotinib treatment, suggesting that pyrotinib may be associated with outcomes of immunotherapy. With the large cell numbers analyzed, we distinguished an isolated, small subpopulation of cells characterized by the enriched expression of MGP, COL1A1, COL1A2, SPARC, and COL3A1 along with the elevated EMT and angiogenesis scores, suggesting its critical role in pyrotinib resistance. Collectively, our study for the first time reveals the transcriptomic evolution of NSCLC cells in response to pyrotinib administration at the single-cell resolution, providing new insights into potential mechanisms of resistance to this novel regimen in NSCLC. Citation Format: Xinfeng Wang, Yuan Li, Runsen Jin, Nan Sun, Jie He. Single-cell analysis sheds light on the resistance mechanisms of a novel pan-HER inhibitor, pyrotinib, in non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5349.

3 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
LLLiu Leo Liu
Liu Leo Liu
XWXin-Feng Wang
Xin-Feng Wang
CHChaopeng Hu
Chaopeng Hu
JLJiancheng Li
Jiancheng Li
RWRui Wei
Rui Wei
XZXin Zhang
Xin Zhang
The synthesis of heteronuclear alkyne analogs incorporating heavier group 14 elements (R1−C≡E−R2, E = Si, Ge, Sn, Pb) has posed a longstanding challenge, with no previous reports on isolable compounds of this nature. Until now, neutral silynes (R1−C≡Si(L)−R2) and germynes (R1−C≡Ge(L)−R2) stabilized by a Lewis base have achieved sufficient stability for structural characterization at low temperatures. Here we show the isolation of a base-free stannyne (R1−C≡Sn−R2) at room temperature, achieved through the strategic use of a bulky cyclic phosphino ligand in combination with a bulky terphenyl substituent. Despite an allenic structure with strong delocalization of π-electrons, this compound exhibits adjacent ambiphilic carbon and tin centers, forming a unique carbon-tin multiple bond with ionic character. The stannyne demonstrates reactivity similar to carbenes or stannylenes, reacting with 1-adamantyl isocyanide and 2,3-dimethyl-1,3-butadiene. Additionally, its carbon-tin bond can be saturated by Et3N·HCl or cleaved by isopropyl isocyanate.